HRMY vs LLY

Harmony Biosciences maintains a strong core business anchored by WAKIX, with 2026 revenue guidance reiterated at $1.0-$1.04 billion, indicating continued market penetration and robust growth (21.1% YoY revenue growth in Q4 2025). The company's attractive valuation (P/E 11.84, PEG 0.43) and strong average annual earnings growth (32.6%) suggest undervaluation relative to its sector. However, the sig...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...